July 07, 2024
2 min watch
PARK CITY, Utah — On this Healio Video Perspective from Medical Trials on the Summit, Carolyn Sasse of Astellas highlights the corporate’s ophthalmology pipeline.
Sasse gives updates about post-marketing security information for Izervay (avacincaptad pegol intravitreal resolution) and a part 1 trial that’s at the moment recruiting sufferers with geographic atrophy secondary to age-related macular degeneration.
“Over the previous decade, now we have established a number one early-stage ophthalmology pipeline that features cell and gene therapies to deal with illnesses corresponding to geographic atrophy and glaucoma, in addition to inherited retinal illnesses corresponding to Stargardt and retinitis pigmentosa,” she mentioned.